Jaka Dernovšek (Avtor), Živa Zajec (Avtor), Goran Poje (Avtor), Dunja Urbančič (Avtor), Tjaša Goričan (Avtor), Simona Golič Grdadolnik (Avtor), Irena Mlinarič-Raščan (Avtor), Andrej Emanuel Cotman (Avtor), Nace Zidar (Avtor), Tihomir Tomašić (Avtor)

Povzetek

The development of new anticancer agents is one of the most urgent topics in drug discovery. Inhibition of molecular chaperone Hsp90 stands out as an approach that affects various oncogenic proteins in different types of cancer. These proteins rely on Hsp90 to obtain their functional structure, and thus Hsp90 is indirectly involved in the pathophysiology of cancer. However, the most studied ATP-competitive inhibition of Hsp90 at the N-terminal domain has proven to be largely unsuccessful clinically. Therefore, research has shifted towards Hsp90 C-terminal domain (CTD) inhibitors, which are also the focus of this study. Our recent discovery of compound C has provided us with a starting point for exploring the structure-activity relationship and optimising this new class of triazole-based Hsp90 inhibitors. This investigation has ultimately led to a library of 33 analogues of C that have suitable physicochemical properties and several inhibit the growth of different cancer types in the low micromolar range. Inhibition of Hsp90 was confirmed by biophysical and cellular assays and the binding epitopes of selected inhibitors were studied by STD NMR. Furthermore, the most promising Hsp90 CTD inhibitor 5x was shown to induce apoptosis in breast cancer (MCF-7) and Ewing sarcoma (SK-N-MC) cells while inducing cause cell cycle arrest in MCF-7 cells. In MCF-7 cells, it caused a decrease in the levels of ERα and IGF1R, known Hsp90 client proteins. Finally, 5x was tested in zebrafish larvae xenografted with SK-N-MC tumour cells, where it limited tumour growth with no obvious adverse effects on normal zebrafish development.

Ključne besede

cancer;Hsp90;inhibitor;Ewing sarcoma;zebrafish;

Podatki

Jezik: Angleški jezik
Leto izida:
Tipologija: 1.01 - Izvirni znanstveni članek
Organizacija: UL FFA - Fakulteta za farmacijo
UDK: 615.4:54:616-006
COBISS: 199197699 Povezava se bo odprla v novem oknu
ISSN: 0753-3322
Št. ogledov: 347
Št. prenosov: 70
Ocena: 0 (0 glasov)
Metapodatki: JSON JSON-RDF JSON-LD TURTLE N-TRIPLES XML RDFA MICRODATA DC-XML DC-RDF RDF

Ostali podatki

Sekundarni jezik: Slovenski jezik
Sekundarne ključne besede: Hsp90;inhibitorji;Ewingov sarkom;zebrafish;Rak (medicina);Farmacevtska kemija;
Vrsta dela (COBISS): Članek v reviji
Strani: 29 str.
Letnik: ǂVol. ǂ177
Zvezek: [article no.] 16941
Čas izdaje: 2024
DOI: 10.1016/j.biopha.2024.116941
ID: 24930191